LISATA THERAPEUTICS I

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

03 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

17 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

12 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

18 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

10 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

13 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

28 May 2024 07:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

20 May 2024 07:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 15:05:01 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

23 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

09 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

03 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

21 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire